Biotin-thiamine-responsive basal ganglia disease
Biotin-thiamine-responsive basal ganglia disease(BTBGD) is a rare disease that affects the nervous system, particularly thebasal gangliain the brain.[4]It is a treatable neurometabolic disorder withautosomal recessiveinheritance.[2][1]First described in 1998[6]and then genetically distinguished in 2005,[7]the disease is characterized by progressive brain damage that, if left untreated, can lead to coma and/or death.[1]Commonly observed in individuals with BTBGD is recurring subacuteencephalopathyalong with confusion, seizures, and disordered movement (hypokinesia).[8]
| Biotin-thiamine-responsive basal ganglia disease (BTBGD) | |
|---|---|
| Other names | BTRBGD,[1]Biotin-responsive basal ganglia disease (BBGD),[2]Thiamine metabolism dysfunction syndrome 2 (biotin or thiamine-responsive type) (THMD2),[3]Thiamine-responsive encephalopathy, Thiamine transporter-2 deficiency[4] |
| Specialty | Neurometabolic disorders, neurology, internal medicine |
| Symptoms | Subacute encephalopathy; dystonia; spasticity; seizures; dysphagia; ataxia; dysarthria; etc.[5] |
| Usual onset | Childhood (ages 3-10)[4] |
| Duration | Lifelong |
| Causes | Family history (inherited)[2] |
| Risk factors | Febrile illness; stress; trauma[5] |
| Diagnostic method | Based on symptoms, family history, brain imaging, genetic testing[5] |
| Management | |management= Prevention of symptoms, avoiding stressors, and routine surveillance[5] |
| Medication | Administering biotin and thiamine; symptomatic treatments[5] |
BTBGD has several alternate names, including:
Signs and Symptoms
editThe onset of signs and symptoms can occur at any age but is most common in childhood between the ages of 3 and 10.[4]Less commonly, it may present in early infancy or adulthood. The neurological symptoms usually present as episodes of increasing severity. A less common exhibition of BTBGD involves persistent symptoms, rather than recurrent episodes.[4]In these cases, fewer symptoms are usually present, with their severity slowly increasing over time.[citation needed]
Classic Presentation (Childhood)
editRecurrent subacute encephalopathy is the most commonly observed symptom, followed bydystonia,both of which are nearly always present. Additional observed symptoms includespasticityor cogwheel rigidity,seizures,difficulty swallowing (dysphagia),ataxia,slurred speech (dysarthria),ophthalmoplegia,opisthotonus,facial palsy,confusion,hyperreflexia,Babinski responses, and ankleclonus.[5]
Early Infancy Presentation
editIn early infancy, the presentation of BTBGD is considered asLeigh-like syndromeor atypical infantile spasms.[5]It is characterized by acute encephalopathy, vomiting, metabolic acidosis (specifically lactic acidosis), and poor feeding during the first 3 months of life.[1][5]
Late-Onset Presentation (Adulthood)
editPresentation of late-onset BTBGD is considered aWernicke-like encephalopathy.[1][5]It is characterized by ataxia, ophthalmoplegia, double vision (diplopia), rapid and uncontrollable eye movement (nystagmus),status seizures,and droopy eyelid(ptosis).The onset of signs and symptoms for adulthood presentation occurs during or after the second decade of life.[citation needed]
Causes
editGenetics
editSLC19A3gene mutations cause BTBGD.[4]SLC19A3is a gene on chromosome 2q36.3 that encodes the proteinthiamine transporter 2.[4][5]Thiamine transporter 2 movesthiamine (vitamin B1)into cells, which is essential for nervous system functioning. Mutations of the gene encoding this protein (SLC19A3) are likely to impair the functioning of this protein and inhibit the transportation and absorption of thiamine.[citation needed]
The role of biotin in BTBGD is unclear.[4]
Triggers
editEpisodes of symptoms can be triggered by several things:[5]
- Febrile illness
- Stress
- Trauma
Diagnosis
editBTBGD can be diagnosed based on brain imaging and confirmed withgenetic testing.[9]Additional diagnostic tools include laboratory testing of biological fluids and reviewing autosomal recessive inheritance in the family history.[citation needed]
Clinical Findings
editBrain Magnetic Resonance Imaging (MRI)
editThe MRI of individuals with BTBGD may reveal lesions on the basal ganglia and central bilateral necrosis in the caudate nucleus and putamen.[7][10]Vasogenic edema is also characteristic of BTBGD.[5]Additional MRI findings include high T2signal intensity with possible swelling in basal ganglia, and abnormal diffuse involvement of the subcortical white matter, cortical, and infratentorial brain.[5][11]Involvement in the thalami, brain stem, and cerebellum may also be observed.[11]
Molecular Genetic Testing
editMolecular genetic tests that can be performed for BTBGD include:[5]
- Sequence analysis of the entire coding region or select exons
- Duplication/deletion analysis
- Targeted variant analysis
Differential Diagnosis
editOther disorders that present similar clinical findings include:[5]
Screening
editFamily members of individuals with BTBGD may be tested regardless of symptoms.[12]Family members may be affected by the disease, may be asymptomatic carriers of the mutation, or may be completely unaffected.[5]Genetic testing of family members allows for the identification of subtle symptoms, asymptomatic carriers, and increased-risk individuals, which allows for early treatment as needed.[citation needed]
Treatment
editTreatment of BTBGD is done to manage specific symptoms and concerns.[5]If left untreated, the disease can be fatal. Treatment may vary by symptom, though it is common to administer thiamine (up to 40 mg/kg/day) and sometimes biotin (5-10 mg/kg/day) orally. This treatment is specifically used to address neurological symptoms and can reverse these symptoms if taken early enough. Biotin and thiamine oral therapy must continue throughout the entirety of the individual's life.[5]Other symptomatic treatments include anti-seizure medication to treat seizures andtrihexyphenidylorL-dopato treat dystonia. Rehab and therapy are used for developmental and social concerns.[citation needed]
Management
editManagement of BTBGD includes prevention of symptoms and routine surveillance.[5]Avoiding stressors is essential in managing BTBGD since stress and trauma can trigger episodes. Fevers are also triggers, so fever control is important. Other triggers that should be avoided include infections and excessive exercise. Routine surveillance should include evaluation of the individual's nervous system, education and development, and any other relevant areas.[citation needed]
Epidemiology
editThe prevalence of BTBGD is unknown.[4]Of the reported cases, it is predominately observed in individuals from Arab populations.
References
edit- ^abcdefAl-Anezi A, Sotirova-Koulli V, Shalaby O, Ibrahim A, Abdulmotagalli N, Youssef R, Hossam El-Din M (April 2022)."Biotin-thiamine responsive basal ganglia disease in the era of COVID-19 outbreak diagnosis not to be missed: A case report".Brain & Development.44(4): 303–307.doi:10.1016/j.braindev.2021.12.003.PMC8696467.PMID34953623.
- ^abcd"Biotin-thiamine-responsive basal ganglia disease - About the Disease - Genetic and Rare Diseases Information Center".rarediseases.info.nih.gov.Retrieved2022-11-27.
- ^abc"#607483 - THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2".omim.org.Retrieved2022-11-27.
- ^abcdefghij"Biotin-thiamine-responsive basal ganglia disease: MedlinePlus Genetics".medlineplus.gov.Retrieved2022-11-27.
- ^abcdefghijklmnopqrsTabarki, Brahim; Al-Hashem, Amal; Alfadhel, Majid (1993), Adam, Margaret P.; Mirzaa, Ghayda M.; Pagon, Roberta A. (eds.),"Biotin-Thiamine-Responsive Basal Ganglia Disease",GeneReviews,University of Washington, Seattle,PMID24260777,retrieved2022-11-27
- ^Ozand PT, Gascon GG, Al Essa M, Joshi S, Al Jishi E, Bakheet S, et al. (July 1998)."Biotin-responsive basal ganglia disease: a novel entity".Brain.121 ( Pt 7) (7): 1267–1279.doi:10.1093/brain/121.7.1267.PMID9679779.
- ^abZeng WQ, Al-Yamani E, Acierno JS, Slaugenhaupt S, Gillis T, MacDonald ME, et al. (July 2005)."Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3".American Journal of Human Genetics.77(1): 16–26.doi:10.1086/431216.PMC1226189.PMID15871139.
- ^"Biotin thiamine responsive basal ganglia disease".Orphanet.Retrieved2022-11-27.
- ^Majumdar S, Salamon N (March 2022)."Biotin-thiamine-responsive basal ganglia disease: A case report".Radiology Case Reports.17(3): 753–758.doi:10.1016/j.radcr.2021.12.029.PMC8717433.PMID35003475.
- ^Alfadhel M, Umair M, Almuzzaini B, Alsaif S, AlMohaimeed SA, Almashary MA, et al. (October 2019)."Targeted SLC19A3 gene sequencing of 3000 Saudi newborn: a pilot study toward newborn screening".Annals of Clinical and Translational Neurology.6(10): 2097–2103.doi:10.1002/acn3.50898.PMC6801173.PMID31557427.
- ^abAlfadhel M, Almuntashri M, Jadah RH, Bashiri FA, Al Rifai MT, Al Shalaan H, et al. (June 2013)."Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases".Orphanet Journal of Rare Diseases.8(1): 83.doi:10.1186/1750-1172-8-83.PMC3691666.PMID23742248.
- ^Aljabri MF, Kamal NM, Arif M, AlQaedi AM, Santali EY (October 2016)."A case report of biotin-thiamine-responsive basal ganglia disease in a Saudi child: Is extended genetic family study recommended?".Medicine.95(40): e4819.doi:10.1097/MD.0000000000004819.PMC5059037.PMID27749535.